Business Context and Reporting Period
This Form 6-K filing by NeuroSense Therapeutics Ltd. covers the month of January 2022, specifically dated January 4, 2022. The report details a material change in the composition of the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
- Board Resignation: Yael German resigned from the Board of Directors effective January 4, 2022, to accept an appointment as the Israeli ambassador to France.
- Board Appointment: Dr. Revital Mandil-Levin was appointed as a new Class I director to replace Ms. German, effective immediately. Her term will expire at the 2022 annual general meeting of shareholders.
Management Commentary and Background
Management highlighted Dr. Mandil-Levin's extensive background in the biotech and pharmaceutical sectors, including over 15 years of experience in startups and product development. Key highlights of her experience include:
- Current CEO and founder of Nanocarry Therapeutics Ltd., focusing on biologics delivery across the blood-brain barrier.
- Former VP Corporate Development at Anima Biotech and Chief Business Development Officer at CollPlant Ltd.
- Former VP Business Development at NeuroDerm Ltd., where she played a major role in the company's $1.1 billion acquisition by Mitsubishi Tanabe Pharma Corporation.
- Former VP Business Development at HealOr Ltd. and Business Development Manager at Proteologics Ltd.
- She holds a PhD in Biochemistry from Bar-Ilan University and an MBA from the Israeli College of Management School of Business.
Key Facts for Investor Verification
- Confirm the effective date of Dr. Mandil-Levin's appointment and her specific term expiration date.
- Verify the impact of the board change on the Company's strategic direction, particularly regarding CNS indications and business development.
- Check subsequent filings for any financial updates or operational milestones not included in this governance-focused report.